Therapeutic Inhibition of PhosphoTau in the Primate Prefrontal Cortex

Abnormal phosphorylation of tau is a classical hallmark of Alzheimer’s and some other neurodegenerative diseases.
Fine detail analysis of the cellular location of various signaling components in the primate prefrontal cortex (PFC) identified a mechanism whereby phosphorylated tau accumulates with aging.
Based on this hypothesis, chronic treatment (daily for 6 months) with low doses of a known, now generic, therapeutic was shown to enhance cognition and reduce the level of phosphorylated tau in the primate PFC (see figure).
A patent application has been filed on this use of the low dose of this generic compound.